Zevra Homepage.
icon news News icon investors Investors icon careers Careers icon contact Contacts
Home > Latest > Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight

Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight

About Us
Our Mission & Vision The Zevra Story Leadership Board of Directors What We Do Partnering
Patients & Caregiver
Clinical Trials Expanded Access Policy Niemann-Pick Disease Type C Urea Cycle Disorders Vascular Ehlers-Danlos Sleep Disorders
Our Products
MIPLYFFA® OLPRUVA® AZSTARYS®
Our Pipeline
Pipeline Clinical Trials Publications & Presentations Medical Literature Medical Information Investigator-Initiated Studies
Careers
Culture Job Openings
Investors
Investor Relations Events & Presentations Stock Quote & Chart Press Releases Corporate Governance SEC Filings Contact Email Alerts
Contact [email protected] 888.958.1253
Footer link Zevra Facebook
Footer link Zevra X twitter
Footer link Zevra linkedin
© 2026 Zevra Therapeutics.
All rights reserved.
|
 Privacy Policy
|
 Notice at Collection
|
 Your Privacy Choices
|
 Terms of Use